Saphenous Vein Grafts Market By Application (Coronary Artery Bypass Grafting, Peripheral Vascular Bypass, Carotid Endarterectomy Support); By Harvesting Technique (Open Vein Harvesting, Endoscopic Vein Harvesting); By End User (Hospitals, Cardiac Specialty Clinics, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Saphenous Vein Grafts Market is projected to expand at a steady pace, with an estimated valuation of USD 543.7 million in 2024, and anticipated to reach around USD 718.4 million by 2030, growing at a CAGR of 4.7% during the forecast period, based on Strategic Market Research’s internal estimates.

 

Saphenous vein grafts (SVGs) have long served as the workhorse of coronary artery bypass grafting (CABG), especially when multiple vessels are involved. While arterial grafts like the internal mammary artery are gaining favor due to durability, SVGs continue to dominate in volume — largely due to accessibility, harvesting ease, and surgeon familiarity. But the market isn’t static. Between 2024 and 2030, subtle but impactful shifts are reshaping how and where these grafts are used.

 

What’s driving the demand? A few converging forces. First, cardiovascular disease remains the world’s top killer, and CABG remains a frontline intervention — particularly in multi-vessel disease and diabetic patients. Second, the population undergoing bypass surgery is aging and increasingly complex, with comorbidities that favor venous over arterial grafting. And third, surgical technologies are evolving. Harvesting techniques like endoscopic vein harvesting (EVH) and tissue-preserving methods are improving graft quality, which is prolonging graft patency — and by extension, trust in SVGs.

 

There’s also a notable uptick in hybrid procedures, where SVGs are combined with stents or robotic assistance. These newer protocols don’t displace vein grafts — they reposition them. Some hospitals now treat SVGs as a complement to precision cardiology, not a legacy tool.

 

At the industry level, medical device manufacturers are innovating around vein preparation systems, graft preservation, and anti-thrombotic surface coatings. We’re also seeing biotech companies investing in genetically engineered or decellularized graft options to address long-term failure risks.

 

Public health trends play a role too. As universal healthcare schemes in Europe and Asia expand cardiac surgical coverage, CABG volumes are growing even in middle-income settings. That’s good news for the SVG market — which remains the most cost-efficient graft option. On the regulatory front, agencies are tightening standards around graft quality, donor tissue management, and post-op imaging — which could lead to product stratification.

 

The ecosystem spans more than just surgeons and OEMs. Payers, hospital administrators, clinical trial networks, and post-op care providers all influence adoption. Even AI-guided preoperative planning is starting to affect graft selection decisions.

 

Bottom line: SVGs may be traditional, but they’re not outdated. This market is no longer about “just another vein.” It’s about optimizing an old tool for a new generation of cardiovascular medicine.

 

Market Segmentation And Forecast Scope

The saphenous vein grafts market can be segmented across four major dimensions — each one reflecting how cardiovascular surgeons, hospitals, and suppliers approach procedural strategy and clinical risk.

By Application

• Coronary Artery Bypass Grafting (CABG)

• Peripheral Vascular Bypass

• Carotid Endarterectomy Support

The lion’s share of demand — over 82% in 2024 — stems from CABG procedures, which continue to be the most frequent indication for SVGs globally. These grafts are preferred for their length and caliber, especially in multi-vessel coronary disease. That said, peripheral bypass surgeries are showing a modest uptick, particularly in patients with critical limb ischemia, where autologous veins are favored over prosthetics due to infection risk.

 

By Harvesting Technique

• Open Vein Harvesting

• Endoscopic Vein Harvesting (EVH)

EVH is gaining fast, especially in North America and Europe. It reduces wound complications, shortens hospital stays, and lowers infection rates. Hospitals with cardiac centers of excellence now consider EVH a standard of care. However, in developing markets, open harvesting still dominates, mainly due to lower upfront equipment costs and limited training.

 

By End User

• Hospitals

• Cardiac Specialty Clinics

• Academic & Research Institutes

Hospitals remain the primary users, accounting for the vast majority of graft volumes. Most procedures are performed in high-acuity surgical settings with access to on-pump or off-pump CABG protocols. Cardiac specialty clinics, often attached to private chains in urban areas, are beginning to adopt vein harvesting and graft prep systems for streamlined operations. Academic institutions, meanwhile, play a different role — often testing novel vein-preservation protocols and trialing coated or hybrid grafts in controlled environments.

 

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

While North America and Europe dominate in terms of revenue, Asia Pacific is the fastest-growing region — driven by rising cardiac surgery volumes, expanded insurance coverage, and hospital infrastructure upgrades in countries like India and China.

 

Scope Note: This segmentation isn’t just clinical — it’s becoming operational. Some suppliers now offer fully integrated SVG kits tailored by region or surgical protocol. Others are bundling vein grafts with imaging, heparin-bonded coatings, or pre-op prep devices — creating procedural ecosystems rather than standalone products.

The forecast scope from 2024 to 2030 includes full market revenue analysis by region, procedure type, harvesting technique, and end-user segment. Both unit volume and ASP trends will be monitored, with special attention to evolving reimbursement frameworks and regional standard-of-care variations.

 

Market Trends And Innovation Landscape

The saphenous vein grafts market is evolving — not through disruption, but through steady reinvention. This isn’t a space chasing hype. It’s one quietly shaped by smarter harvesting, better preservation, and a deeper understanding of long-term graft viability.

Smarter Harvesting Is Becoming Standard

The shift from open vein harvesting to endoscopic vein harvesting (EVH) isn’t just about aesthetics or quicker recovery — it’s about long-term outcomes. Studies increasingly show that grafts harvested with minimal trauma maintain endothelial integrity better. That translates to improved patency. So hospitals are investing in EVH systems not just to reduce infections, but to protect the vein’s internal lining during extraction.

OEMs are responding with more ergonomic EVH kits, improved visualization, and pressure-controlled CO2 insufflation systems to minimize endothelial shear stress.

One cardiovascular surgeon at a U.K. teaching hospital noted: “What matters most is not how fast you harvest, but how gently.” That thinking is becoming widespread.

 

Coated and Bioengineered Grafts Are in Focus

A major challenge in SVG use is long-term failure due to intimal hyperplasia and thrombosis. This is where surface science is coming into play. A few companies are advancing heparin-coated and nitric oxide-releasing vein grafts, aiming to extend patency beyond the 5-year benchmark. Some even incorporate anti-inflammatory polymer films to reduce early immune response.

In the pipeline: bioengineered, decellularized vein scaffolds, seeded with autologous cells. These next-gen grafts are still in clinical trials, but they signal a clear ambition: making venous grafts behave more like arterial conduits.

 

Preservation Is the New Battleground

Post-harvest handling is no longer treated as an afterthought. The industry is seeing a surge in graft preservation systems that regulate pressure, temperature, and exposure time. Products that maintain physiologic pressure gradients or oxygenated storage are now used in high-volume CABG centers to prevent endothelial injury during transit.

Expect this trend to grow — especially as payers begin to link post-op graft failure rates to overall procedure quality metrics.

 

AI Is Entering Pre-Surgical Planning

While AI isn’t modifying the graft itself, it’s starting to influence how graft selection is made. Planning software that integrates angiography, patient comorbidity, and risk stratification can now suggest the optimal mix of arterial and venous grafts per patient. This could shift how many SVGs are used per procedure — especially in complex or redo surgeries.

This use of AI isn’t replacing surgeon judgment. It’s guiding procedural design before a scalpel is ever picked up.

 

3D-Printed Vein Models Are Assisting in Training

Academic centers are now using 3D-printed models of saphenous veins to simulate harvesting and anastomosis. These tools aren’t for patients — they’re for surgical teams. They’re helping new cardiovascular fellows train on vein prep and graft handling in a low-risk environment.

It’s a small innovation with a big outcome: fewer early-career harvesting errors, which means better long-term graft outcomes.

To be honest, this market won’t see a radical overhaul overnight. But the direction is clear. SVGs are being refined at every stage — from harvest to preservation to implantation. And those refinements are giving hospitals, surgeons, and patients a reason to keep trusting them.

 

Competitive Intelligence And Benchmarking

Despite being a mature market, the saphenous vein grafts space isn’t dominated by a single player — it’s shaped by a mix of surgical device firms, cardiovascular OEMs, and biotech innovators. While vein grafts themselves are biologic materials, the tools, coatings, and preservation systems built around them are where competition heats up.

Here’s a look at the companies shaping the landscape — and how they’re differentiating.

Terumo Corporation

A long-time player in cardiovascular surgery, Terumo has built strong credibility in vein harvesting systems, particularly its VirtuoSaph ® EVH System, which is used globally. The company positions itself on endothelial preservation and minimally invasive access, often emphasizing clinical data on reduced wound complications.

Their edge? Consistency across markets. Whether it’s a cardiac center in Germany or Brazil, Terumo’s systems tend to be the default — especially where outcomes data is prioritized by payers.

 

Getinge AB (Maquet)

Getinge, through its Maquet division, is another heavyweight in the EVH ecosystem. Their VASOVIEW® product line is widely used in the U.S. and Europe. What sets them apart is how they integrate vein harvesting into a broader cardiovascular suite — including heart-lung machines and aortic clamps.

This system-level integration appeals to surgical teams building full-service bypass programs, especially in public hospitals and academic centers.

 

LeMaitre Vascular

Focused more tightly on vascular surgery, LeMaitre specializes in devices for both open and minimally invasive vein harvesting. They’ve also invested in vascular biologics, offering preserved human saphenous veins for complex peripheral reconstructions.

LeMaitre’s play is unique: they’re not just supporting CABG — they’re pushing into critical limb ischemia and trauma bypass where autologous vein grafts are scarce.

 

Artivion (formerly CryoLife)

A niche but growing player, Artivion offers CryoVein ®, a cryopreserved allograft version of the saphenous vein. While not mainstream, these grafts are vital in salvage procedures, infected fields, or redo surgeries where autologous veins are no longer viable.

Their positioning is clinical rather than volume-driven — targeting high-risk vascular reconstruction cases in specialized centers.

 

Saphena Medical (acquired by Vasoview license holder)

This startup-turned-acquired brand focused on next-generation EVH tools, including single-use kits with improved ergonomics and cost-efficiency. While now under larger corporate umbrellas, their innovations live on in more intuitive harvesting systems that reduce the learning curve for newer surgeons.

Their legacy? Making EVH more scalable — particularly in regions where surgical staffing or training is limited.

 

Edwards Lifesciences & Boston Scientific

These companies aren’t in the grafts market directly — but their influence is indirect. Both have invested in hybrid revascularization and minimally invasive CABG, which shifts how and when vein grafts are used. Their cardiac support systems and stent technologies are reshaping surgical protocols.

In a way, they’re reshuffling procedural decisions, which impacts graft volume and type, especially in off-pump or robotic-assisted surgeries.

 

Competitive Dynamics at a Glance:

• Terumo and Maquet dominate EVH adoption, especially in high-volume centers across developed markets.

• LeMaitre and Artivion own the biologic and peripheral graft niches, where custom use cases and high-risk cases matter more than volume.

• Newer players are working to make vein harvesting more cost-accessible and operator-friendly, opening doors in lower-income markets.

• As CABG moves toward hybrid models, companies that integrate vein harvesting with other procedural tools are gaining ground.

At its core, this market rewards two things: trust and long-term patency. The vendors who build around both — with tech, training, and outcome data — are the ones pulling ahead.

 

Regional Landscape And Adoption Outlook

The use and evolution of saphenous vein grafts (SVGs) vary sharply by geography. While the technique itself is globally standard, how SVGs are harvested, preserved, and selected reflects deeper differences in infrastructure, training, and procedural volume. Some regions are pushing vein graft innovation; others are still scaling up basic cardiac surgery capacity.

North America

North America — especially the United States — leads in endoscopic harvesting adoption and graft quality optimization . Nearly all major cardiac centers now use EVH systems, and many hospitals bundle vein graft prep with enhanced post-op monitoring.

The U.S. market also sees strong uptake of coated or preserved graft solutions, often driven by quality-linked reimbursement models. Centers of excellence, like Cleveland Clinic or Mayo Clinic, invest heavily in both graft patency research and training programs for EVH.

However, CABG volumes in the U.S. are slightly declining due to increased PCI usage in single-vessel disease. That said, SVGs remain vital for diabetic, elderly, and complex multi-vessel patients — keeping the market resilient.

 

Europe

Europe mirrors the U.S. in procedural quality, but not in pace. Germany, the UK, and the Netherlands have mature cardiac surgery systems with high EVH penetration and structured outcomes tracking. France and Scandinavia are leading adopters of heparin-coated grafts and pressure-controlled preservation systems.

Where Europe differs is in centralization — most CABG cases are funneled to large, public hospitals, which supports bulk procurement of SVG tools and systems . This has led to regional tenders that favor suppliers with integrated EVH and graft prep portfolios.

Eastern Europe presents a mixed picture. Countries like Poland and Hungary are expanding CABG capacity but still rely heavily on open harvesting due to budget and training gaps.

 

Asia Pacific

This is the fastest-growing region for SVGs — but also the most uneven.

In China and India, the rise in coronary artery disease, improved surgical infrastructure, and expanded cardiac insurance coverage are all boosting CABG volumes. SVGs remain the go-to graft type due to cost and availability .

Yet EVH adoption is still low outside tier-1 hospitals. In many Indian cardiac centers, open vein harvesting remains the norm, though portable EVH systems are slowly being introduced.

 

Japan and South Korea, on the other hand, are at the high end of the spectrum. Their hospitals are piloting cryopreserved graft options, AI-supported pre-op planning, and advanced vein preservation protocols .

Asia Pacific is the region where volume meets variability — and that’s attracting global OEMs looking to scale next-gen graft tools.

 

Latin America

SVG use here is growing steadily, but with regional pockets of excellence .

Brazil and Mexico have advanced cardiac surgery centers using EVH and exploring coated grafts. Public health programs are increasingly covering CABG in diabetic populations, which tend to need multi-vessel grafting.

However, in countries like Argentina, Peru, and Colombia, many hospitals still depend on manual harvesting techniques, and graft quality preservation varies widely. Training partnerships and subsidized EVH kits are beginning to close this gap.

 

Middle East & Africa (MEA)

This region is underpenetrated but slowly mobilizing . In the Gulf states — notably Saudi Arabia and the UAE — government investments in tertiary care hospitals are creating demand for full cardiac suites, including modern EVH and vein graft preservation tools.

But across most of Africa, access to cardiac surgery remains limited. Where CABG does occur, SVGs are usually harvested via open techniques with minimal post-harvest management. NGO-funded programs and training missions from international cardiac groups are driving slow but steady improvement.

 

Regional Summary:

• North America & Europe : Mature, outcome-driven markets pushing coated and preserved graft innovations.

• Asia Pacific : Highest growth potential — massive procedure volume but inconsistent technique standardization.

• Latin America : Growing CABG footprint, uneven technology access.

• Middle East & Africa : Emerging cardiac surgery hubs in select geographies; low base for SVG volumes.

The takeaway? Vein graft demand isn’t just tied to disease prevalence. It’s tied to surgical capability, training infrastructure, and how much a health system is willing to invest in long-term cardiac outcomes.

 

End-User Dynamics And Use Case

In the saphenous vein grafts market, demand isn’t just driven by procedure volume — it’s shaped by the type of facility, surgical team expertise, and infrastructure readiness . From tertiary hospitals to regional clinics, each end user segment plays a different role in how SVGs are selected, harvested, and preserved.

1. Tertiary and Academic Hospitals

These are the frontline institutions performing high-complexity CABG surgeries, often including multi-vessel disease, redo operations, and hybrid procedures.

What sets them apart?

• Routine use of endoscopic vein harvesting (EVH)

• Adoption of heparin-bonded or cryopreserved grafts

• Real-time imaging and AI-supported surgical planning

• Specialized teams: cardiothoracic surgeons, perfusionists, vein harvest technicians

They also serve as testing grounds for innovation . Whether it’s pressure-regulated graft prep systems or early-phase bioengineered veins, these hospitals are usually first adopters.

 

2. Community and Regional Hospitals

These centers handle more routine CABG cases. Often, they use open vein harvesting, especially where EVH systems haven’t yet been adopted or fully reimbursed. These hospitals:

• Prioritize cost-efficiency over innovation

• May lack dedicated harvest staff or preservation protocols

• Still rely on autologous grafts without surface coatings

That said, as CABG volumes increase in suburban regions, many are investing in modular EVH kits and remote training tools to bridge the skill gap.

 

3. Private Cardiac Clinics and Specialty Centers

In regions like India, the UAE, and Brazil, high-volume private cardiac clinics are gaining ground. Their model is different: high turnover, optimized ORs, and tech-driven value propositions.

These centers:

• Use EVH as a brand differentiator

• Often bundle vein graft prep with post-op telemonitoring

• Focus heavily on shorter recovery times and aesthetic outcomes

They’re more likely to trial coated vein grafts or advanced prep tools, particularly for affluent or insured patients.

 

4. Research Institutes and Training Hospitals

These centers don’t drive procedure volume — they drive the next wave of graft science .

Examples:

• Simulated harvesting using 3D-printed vein models

• Trials on bioengineered decellularized grafts

• Development of AI-assisted graft quality assessment tools

Their impact? Slow, but significant. Breakthroughs here often enter the commercial market 3–5 years later, especially as data matures.

 

5. Military and Emergency Care Settings (Niche Use)

While niche, military field hospitals and trauma centers occasionally use SVGs in peripheral vascular repair after blast injuries or limb trauma. In such cases, off-the-shelf preserved grafts — either autologous or cryopreserved — are vital.

 

Use Case: Singapore

A cardiac specialty hospital in Singapore recently overhauled its CABG protocols after noticing inconsistent outcomes tied to vein graft quality. The facility shifted from manual open harvesting to a standardized EVH program paired with oxygenated graft preservation chambers .

Within one year, post-op graft failure rates dropped by 26%. Hospital stay durations shortened, and readmission rates for early graft occlusion were halved. Importantly, the cost of EVH kits was offset by reduced complications and fewer surgical revisions.

Lesson? Investing in harvest technique and preservation pays off — not just clinically, but financially.

Bottom line: Whether it’s a high-end surgical institute or a growing regional hospital, each user segment is looking for one thing — a graft that lasts . The companies that understand how each setting defines “quality” are the ones that will lead the next phase of SVG adoption.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Past 2 Years)

• Terumo launched a next-gen EVH system in early 2024, featuring an improved endoscope handle, better tissue sealing, and integrated LED lighting to support harvest precision in low-resource ORs. The company is also piloting a digital vein harvest tracking tool that logs harvest time, pressure changes, and tissue trauma levels — a step toward real-time graft quality scoring.

• LeMaitre Vascular expanded its biologics portfolio in 2023 with a new line of cryopreserved saphenous vein segments tailored for peripheral vascular bypass — particularly in limb salvage cases. These grafts are now being evaluated in rural U.S. hospitals where autologous vein access is limited.

• A German research consortium announced early-stage trials for a polymer-coated saphenous vein graft that slowly releases nitric oxide. The goal is to reduce post-implant thrombosis without systemic anticoagulation. Early in-vivo studies showed promising patency beyond 18 months.

• In India, a cardiac hospital chain introduced a cloud-based EVH training program paired with an AI video overlay that guides junior surgeons during harvesting. The platform tracks incision length, vein handling, and tool angles in real-time — designed to raise EVH competency in tier-2 cities.

• Artivion began expanding its graft preservation solutions to select African and Middle Eastern hospitals. A simplified version of its CryoVein line is being field-tested in trauma-based vascular reconstructions.

 

Opportunities

• Precision Harvesting Meets AI: There’s growing demand for AI-assisted vein harvesting and real-time graft quality analytics . If software can alert surgical teams when a graft is at risk of trauma or twist, it could prevent early failure — saving millions in downstream costs.

• Emerging Market Expansion: Markets in Southeast Asia, Eastern Europe, and Latin America are aggressively scaling CABG capacity. Vein grafts — especially cost-effective, easy-to-train EVH tools — are a logical entry point for suppliers targeting early-stage surgical infrastructure.

• Coated and Bioengineered Grafts: Startups and biotech labs are exploring gene-edited and decellularized vein grafts that could outperform autologous options. While not commercially viable yet, these grafts may soon enter the picture for high-risk, redo CABG patients.

 

Restraints

• High Cost of Advanced Harvest Systems: EVH platforms, coated grafts, and graft preservation devices come at a premium. For general hospitals or public health systems with tight capital budgets, this creates a tough tradeoff: short-term savings vs. long-term outcomes .

• Skill and Training Gaps: In many regions, surgical teams still lack formal training in EVH or vein graft preservation. Even when systems are procured, underutilization remains a barrier. This slows adoption — especially outside of high-income urban centers.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 543.7 Million
Revenue Forecast in 2030	USD 718.4 Million
Overall Growth Rate	CAGR of 4.7% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Application, By Harvesting Technique, By End User, By Geography
By Application	Coronary Artery Bypass Grafting (CABG), Peripheral Vascular Bypass, Carotid Endarterectomy Support
By Harvesting Technique	Open Vein Harvesting, Endoscopic Vein Harvesting (EVH)
By End User	Hospitals, Cardiac Specialty Clinics, Academic & Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, China, India, Japan, Brazil, Saudi Arabia, South Africa, etc.
Market Drivers	- Rising multi-vessel CABG volume in aging populations - Expanded adoption of endoscopic vein harvesting - Innovations in graft preservation and coating technologies
Customization Option	Available upon request